To OTC Journal Members:
 

Comments in the BLOG

It's time for a new BLOG posting on Xenomics (OTC BB: XNOM). XNOM has rocketed up the charts in the last few days. Two months ago I felt this was one of our least likely candidates for a short term move. I have been counseling that the stock was for long term investors only. What do I know? On March 17th we first featured the company at $2.50. The stock is trading at $4.50 today- an 80% return ninety days. This is a refreshing oasis in the 2005 endless desert. The medical community is starting to take note of their transrenal DNA technology. Look for a BLOG posting on this one in the next day or two.

To use the BLOG, simply go to the home page at www.otcjournal.com - the BLOG will scroll down automatically on the right side of your screen. The most current journal entries appear in the middle of your screen. Check back frequently for updates particularly when stocks are moving to overbought or oversold levels or in volatile markets. Your questions and postings do not automatically appear, so don't bother posting the same question multiple times. I personally go through to moderate and respond to every question.
 

Datascension (OTC BB: DSEN); New Hire Paying Dividends

In the March 22nd edition I first featured DSEN. This company has nearly 700 employees and conducts marketing surveys out of their state-of-art technology and telemarketing center in Costa Rica. The market survey business is a $12 billion industry world wide.

Market survey and customer service outsourcing has been moving from the Far East back to this side of the globe as the language barrier has become too cumbersome. DSEN has become the benficiary of that trend.

Datascension achieved $8.6 million in revenues last year, and after a slow start has now logged back to back record months for both sales and revenues in April and May.

The company is uniquely positioned to service both the English and Spanish speaking markets. They have the ability to target the red hot Latino demographic in the US, and can also provide services to Central and South America.

As previously announced, DSEN recently hired a specialist in Southern California to help them penetrate the Latin American market, and that new hire is starting pay dividends already.

Today, after the market closed, DSEN announced it had been retained by MEDirect, a company that sells diabetic supplies directly to Medicare eligible diabetic patients in the Latino community in the US and Puerto Rico. MEDirect is engaging in a TV campaign targeted at the US Spanish Speaking populatoin.

This is the best kind of new business for DSEN, as it is customer service related, and will not cut into existing survey business which only runs about 6 hours per day.

As you can see from the bar chart, the purchasing power of the Latino Community in the US is growing exponentially and is expected to eclipse the $1 trillion mark by year 2010.

Furthermore, the statistics associated with Latino Type II Diabetes in the US are quite eye opening:

• The prevalence of type 2 diabetes is 1.5 times higher in Latinos than non-Latino whites.
• Two million or 8.2% of all Latino Americans aged 20 years or older have diabetes.
• Approximately 24% of Mexican Americans in the United States and 26% of Puerto Ricans between the ages of 45-74 have diabetes.
• Nearly 16% of Cuban Americans in the United States between the ages of 45-74 have diabetes.

Although it's impossible to say when this stock is going to break out, you can certainly say the stock is camped at a great level for accumulation. It's been camping on Fibonacci's perfect 61.8% retracement level for the last month, simply grinding.

A decent volume surge on the buy side could yield a nice upside move in DSEN as the stock has had months to absorb supplies from sellers. There are only 16 million I&O on this one, and probably only about 4 million in public hands. 

Today's contract announcement give you another reason to own this stock. Strong revenue base, a customer list of Fortune 500 companies, an infrastructure already built out for rapid expansion, and a small float. Sounds like the ingredients for appreciation.
 
 

Here is the complete text of today's news release for your review:
 

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Go Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketByte LLC has been paid a fee of $25,000 and 500,000 newly issued restricted shares by Datascension for coverage of the company.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. 

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services. 

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $140,0000 in Dutchess Private Equities II LP (“the Dutchess Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner.  No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Dutchess Limited Partnership.  The Dutchess Limited Partnership is one of two hedge funds managed by Dutchess Advisors.  Dutchess Advisors periodically refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter.  Dutchess Advisors may or may not own shares in the companies that it so refers to MarketByte.  MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Dutchess Advisors owns any shares in the companies that it refers to MarketByte LLC.  The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.  MarketByte LLC's mailing address is 3525 Del Mar Heights Rd #334, San Diego, CA 92130.